Phathom Pharmaceuticals, Inc.·4

Feb 12, 4:34 PM ET

Basta Steven L 4

4 · Phathom Pharmaceuticals, Inc. · Filed Feb 12, 2026

Research Summary

AI-generated summary of this filing

Updated

Phathom (PHAT) CEO Steven L. Basta Receives Award; Surrenders Shares

What Happened
Steven L. Basta, President, CEO and Director of Phathom Pharmaceuticals (PHAT), had performance stock units vest on Feb 10, 2026. The vesting resulted in issuance of 12,362 shares to him (acquired at $0.00). To satisfy the issuer's tax withholding obligation, 6,277 of those shares were surrendered (disposed) at an attributed price of $12.82 per share, totaling $80,471.

Key Details

  • Transaction date: February 10, 2026; Form 4 filed February 12, 2026 (Period of Report: 2026-02-10). Filing appears timely (within the typical 2-business-day window).
  • Award: 12,362 shares issued upon vesting of performance stock units (PSUs) granted April 3, 2025 (Footnote F1).
  • Tax withholding: 6,277 shares were surrendered to the company to satisfy tax withholding (Footnote F3); attributed value $12.82/share, $80,471 total.
  • Other note: filing references 2,410 shares acquired under Phathom’s employee stock purchase plan in January 2026 (Footnote F2).
  • Shares owned after the transaction: not specified in the provided filing.

Context
This was not an open-market sale; it was issuance of shares on PSU vesting followed by a routine share surrender to cover taxes (a common cashless settlement). Such withholding transactions are administrative and do not necessarily signal a change in the insider’s view of the company.

Insider Transaction Report

Form 4
Period: 2026-02-10
Basta Steven L
DirectorPresident and CEO
Transactions
  • Award

    Common Stock

    [F1][F2]
    2026-02-10+12,362379,592 total
  • Tax Payment

    Common Stock

    [F3]
    2026-02-10$12.82/sh6,277$80,471373,315 total
Footnotes (3)
  • [F1]Represents shares issued upon vesting of performance stock units granted to the reporting person on April 3, 2025 based on the achievement of performance criteria determined to be satisfied on February 10, 2026.
  • [F2]Includes 2,410 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in January 2026.
  • [F3]Represents shares underlying the performance stock units that were surrendered by the reporting person to the Issuer in satisfaction of the Issuer's tax withholding obligation.
Signature
/s/ Steven L. Basta|2026-02-12

Documents

1 file
  • 4
    ownership.xmlPrimary

    4